EUVIMEDEUVIMED entdecken
Fallbericht

Hemangiopericytoma of the skull base: A long-term complete response with trimodality treatment

Meltem K Bolukbas iD, Emine S Akovali iD, Fatma Y Musri iD, Rabia Demirtas iD

Indian Journal of Cancer · 2024

DOI: 10.4103/ijc.ijc_207_21 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Indian Journal of Cancer, 2024. Verfasst von Meltem K Bolukbas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Health Sciences University Erzurum Regional Training and Research Hospital, Caykara Street, Yakutiye-Erzurum, Turke…. Hauptthemen laut MEDLINE: Hemangiopericytoma, Skull Base Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemangiopericytoma (HPC) is a rare tumor originating from Zimmerman pericytes. It constitutes less than 1% of all intracranial tumors. Because of the high recurrence rates, radiotherapy (RT) is a vital step in the treatment, but the timing and dose remain uncertain. We presented a 39-year-old patient with a high-grade hemangiopericytoma located at the skull base. The patient presented with a severe headache. Cranial magnetic resonance imaging (MRI) revealed a mass of size of 60 × 50 mm. A subtotal resection was performed that confirmed the diagnosis of HPC. The patient received 66 Gy postoperative RT. Adjuvant sunitinib treatment was initiated after RT. The complete regression was achieved in the third month after RT. The patient has a complete response for 25 months. To our knowledge, this case is one of the rare cases in the literature in which immediate RT and adjuvant chemotherapy were used in combination with surgery. Although HPC is a radio- and chemo-resistant disease, a trimodality treatment approach can provide the patients with a complete response. In particular, patients with high-grade and inoperable tumors and patients who undergo subtotal resection should be evaluated for trimodal therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiopericytomaSkull Base NeoplasmsHumansAdultCombined Modality TherapyMaleMagnetic Resonance Imaging

Autor:innen und Institutionen

  • Department of Radiation Oncology, Health Sciences University Erzurum Regional Training and Research Hospital, Caykara Street, Yakutiye-Erzurum, Turkey.
  • Department of Medical Oncology, Health Sciences University Erzurum Regional Training and Research Hospital, Caykara Street, Yakutiye-Erzurum, Turkey.
  • Department of Medical Pathology, Ataturk University, Yakutiye-Erzurum, Turkey.

ORCID-Profile: Meltem K Bolukbas, Emine S Akovali, Fatma Y Musri, Rabia Demirtas

Zitieren

APA

Bolukbas, M. K., Akovali, E. S., Musri, F. Y., & Demirtas, R. (2024). Hemangiopericytoma of the skull base: A long-term complete response with trimodality treatment. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_207_21

Vancouver

Bolukbas MK, Akovali ES, Musri FY, Demirtas R. Hemangiopericytoma of the skull base: A long-term complete response with trimodality treatment. Indian Journal of Cancer. 2024. doi:10.4103/ijc.ijc_207_21

BibTeX
@article{Bolukbas2024,
  author = {Bolukbas, Meltem K and Akovali, Emine S and Musri, Fatma Y and Demirtas, Rabia},
  title = {Hemangiopericytoma of the skull base: A long-term complete response with trimodality treatment},
  journal = {Indian Journal of Cancer},
  year = {2024},
  doi = {10.4103/ijc.ijc_207_21}
}
Kostenlos starten →